Cargando…

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment

This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model to predict the maximum plasma concentration (C(max)) and trough concentration (C(trough)) at steady-state of olaparib (OLA) in Caucasian, Japanese and Chinese. Furthermore, the PBPK model was combined with mean and 95%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Dongmei, Wang, Guopeng, Wu, Honghai, Ren, Jiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519932/ https://www.ncbi.nlm.nih.gov/pubmed/37749178 http://dx.doi.org/10.1038/s41598-023-43258-9

Ejemplares similares

Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling
por: Gao, Dongmei, et al.
Publicado: (2023)

Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling
por: Wu, Chunnuan, et al.
Publicado: (2022)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions
por: Gao, Liuliu, et al.
Publicado: (2020)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer
por: Taflin, Helena, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
por: Heimbach, Tycho, et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Palatability and pharmacokinetics of flunixin when administered to sheep through feed
por: Marini, Danila, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection
por: Engwerda, Elsemiek E. C., et al.
Publicado: (2017)

Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
por: Minnema, Jordi, et al.
Publicado: (2022)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Estimation of Pediatric Dosage of Antimalarial Drugs, Using Pharmacokinetic and Physiological Approach
por: Mhango, Ellen K. G., et al.
Publicado: (2023)

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy
por: Li, Gang, et al.
Publicado: (2021)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

A physiologically based pharmacokinetic model to optimize the dosage regimen and withdrawal time of cefquinome in pigs
por: Mi, Kun, et al.
Publicado: (2023)

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects
por: Song, Ivy, et al.
Publicado: (2015)

Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs
por: Vazquez Fuster, Irene B., et al.
Publicado: (2020)

Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption
por: Wang, Zhongjian, et al.
Publicado: (2022)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
por: Jeong, Yoo-Seong, et al.
Publicado: (2021)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
por: Nafziger, Anne N., et al.
Publicado: (2019)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
por: Fukumura, Kazuya, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection
por: Goutelle, Sylvain, et al.
Publicado: (2021)

Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model
por: Mi, Kun, et al.
Publicado: (2022)

Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients
por: Cui, Cheng, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes
por: Ladumor, Mayur K., et al.
Publicado: (2022)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Epinephrine Administered in Anaphylaxis: The Evolution of 0.3 mg Dosage
por: Coady, Peyton, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fatb736mr3e0bdnh9uj41d9ic6